Department of Neurology, Faculty of Medicine, University of Cologne and University Hospital of Cologne, Kerpener Strasse, 62, 50937, Cologne, Germany.
Department of Neurology and Palliative Medicine, Cologne City Hospitals, Cologne, Germany.
J Neurol. 2022 Nov;269(11):5710-5719. doi: 10.1007/s00415-022-11260-2. Epub 2022 Jul 8.
The "coronavirus disease 2019" (COVID-19) pandemic, caused by the "severe-acute-respiratory-syndrome-coronavirus 2" (SARS-CoV-2), challenges healthcare systems worldwide and impacts not only COVID-19 patients but also other emergencies. To date, data are scarce on the extent to which the COVID-19 pandemic impacted status epilepticus (SE) and its treatment.
To assess the influence of the COVID-19 pandemic on the incidence, management and outcome of SE patients.
This is a retrospective, multicentre trial, approved by the University of Cologne (21-1443-retro).
All SE patients from the urban area of Cologne transmitted to all acute neurological departments in Cologne between 03/2019 and 02/2021 were retrospectively analysed and assessed for patient characteristics, SE characteristics, management, and outcome in the first pandemic year compared to the last pre-pandemic year.
157 pre-pandemic (03/2019-02/2020) and 171 pandemic (from 03/2020 to 02/2021) SE patients were included in the analyses. Acute SARS-CoV-2 infections were rarely detected. Patient characteristics, management, and outcome did not reveal significant groupwise differences. In contrast, regarding prehospital management, a prolonged patient transfer to the hospital and variations in SE aetiologies compared to the last pre-pandemic year were observed with less chronic vascular and more cryptogenic and anoxic SE cases. No infections with SARS-CoV-2 occurred during inpatient stays.
SARS-CoV-2 infections did not directly affect SE patients, but the transfer of SE patients to emergency departments was delayed. Interestingly, SE aetiology rates shifted, which warrants further exploration. Fears of contracting an in-hospital SARS-CoV-2-infection were unfounded due to consequent containment measures.
由“严重急性呼吸系统综合征冠状病毒 2 型”（SARS-CoV-2）引起的“2019 年冠状病毒病”（COVID-19）大流行，给全球的医疗保健系统带来了挑战，不仅影响了 COVID-19 患者，还影响了其他紧急情况。迄今为止，关于 COVID-19 大流行对癫痫持续状态（SE）及其治疗的影响程度的数据很少。
评估 COVID-19 大流行对 SE 患者的发病率、治疗和结局的影响。
这是一项回顾性、多中心试验，得到了科隆大学（21-1443-retro）的批准。
对 2019 年 3 月至 2021 年 2 月期间科隆市区所有传送到科隆所有急性神经科病房的 SE 患者进行回顾性分析和评估，比较大流行第一年与大流行前最后一年的患者特征、SE 特征、治疗和结局。
共纳入 157 例大流行前（2019 年 3 月至 2020 年 2 月）和 171 例大流行期间（2020 年 3 月至 2021 年 2 月）的 SE 患者。很少检测到急性 SARS-CoV-2 感染。患者特征、管理和结局在组间没有显著差异。相比之下，在院前管理方面，与大流行前最后一年相比，患者转移到医院的时间延长，SE 的病因也有所变化，慢性血管性 SE 病例减少，而隐源性和缺氧性 SE 病例增多。住院期间没有发生 SARS-CoV-2 感染。
SARS-CoV-2 感染并没有直接影响 SE 患者，但 SE 患者转至急诊的时间被延迟。有趣的是，SE 的病因发生率发生了变化，这需要进一步探讨。由于采取了相应的遏制措施，住院期间感染 SARS-CoV-2 的担忧是没有根据的。
